Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1...
Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic...
View ArticleStudy: Ipilimumab with VEGF inhibitors may be potential option for melanoma...
Among patients with advanced melanoma, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in blood was associated with poor response to treatment with the immunotherapy...
View ArticleAnalysis on long-term outcome in patients treated with pazopanib for...
An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated...
View ArticleTel Aviv University researchers win two prestigious melanoma research awards...
Tel Aviv University researchers won two out of three prestigious melanoma research awards granted this year by The Melanoma Research Alliance and The Saban Family Foundation. The Team Science Awards...
View ArticleCardioCell announces new clinical trials using allogeneic stem-cell therapy...
CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans...
View ArticleBayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets...
Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver...
View ArticleBevacizumab offers no benefit for patients newly diagnosed with glioblastoma
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report...
View ArticleSeno Medical Instruments sells $34.6 million of $39 million Series C equity...
Seno Medical Instruments, Inc., the company pioneering opto-acoustic imaging as a tool to improve the process of diagnosing breast cancer, today announced that it has sold $34.6 million of a $39...
View ArticleRegeneron receives FDA acceptance for EYLEA injection for treatment of...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application...
View ArticleStudy establishes innovative approaches to improve vision of young children...
Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual...
View ArticleBayer Yakuhin submits marketing authorization application in Japan for EYLEA...
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept)...
View ArticleLow-amplitude electric fields help hard-to-heal chronic wounds
Naturally occurring electricity in our cells is key to how our bodies function, and that includes the healing of wounds.
View ArticleBayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients...
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib)...
View ArticleSynta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY...
Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL...
View ArticleRexahn provides updates on clinical development programs, reports full-year...
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development...
View ArticleResearch report on China's bevacizumab market
Research and Markets has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" report to their offering.
View ArticleEuropean Commission approves Exelixis' COMETRIQ for treatment of progressive,...
Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic...
View ArticleResearch may lead the way toward new treatments for proliferative retinopathies
A new report published online in The FASEB Journal may lead the way toward new treatments or a cure for a common cause of blindness (proliferative retinopathies). Specifically, scientists have...
View ArticleBIDMC scientist wins Gairdner Award for landmark discovery in the field of...
Harold F. Dvorak, MD, senior investigator in the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center and former chairman of BIDMC's Department of Pathology, is one of eight...
View ArticleWounds may heal more quickly if exposed to low-intensity vibration, say...
Wounds may heal more quickly if exposed to low-intensity vibration, report researchers at the University of Illinois at Chicago.
View Article
